GSK plc vs Energy Select Sector SPDR Fund — how do they compare? GSK plc trades at $52.59 (market cap $101.34B), while Energy Select Sector SPDR Fund trades at $57.07. The key difference: GSK plc pays a 3.49% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| GSK | XLE | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $62.57 |
52-Week Low | $36.20 | $42.12 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
XLE trades at $57.065, up 0.2% today, with a bullish technical signal from moving averages and strong support at $56. The ETF has gained 21% year-to-date, ranking among top-performing sector SPDRs. Recent news highlights energy sector strength from data center demand and geopolitical tensions, while a dividend of $0.38 is scheduled for June 2026.
Outlook remains positive due to sector earnings growth and oil price stability, but risks include volatile crude markets and competitive pressure from clean energy. Analyst sentiment is mixed, with technical indicators showing overbought conditions near-term.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →